Has the USPSTF gone far enough with its new PCa grade?

"I think the micronized formulation is something to think about," says Gautam Jayram, MD.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by December 29, 2024.

“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.

“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option," says Timothy J. Daskivich, MD.

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.